Liquidia Corporation's Yutrepia has generated approximately $300.3 million in sales during the first half of 2026 since its June 2025 launch, with 5,900 unique prescriptions and more than 5,000 patients initiated on therapy. The inhaled dry-powder treprostinil formulation, approved by the FDA in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, uses Liquidia's proprietary PRINT technology to enable higher doses than marketed inhaled therapies. Liquidia faces competition from United Therapeutics' Tyvaso and Tyvaso DPI, as well as Johnson & Johnson's Ventavis and Uptravi, while advancing pipeline candidate L606 in a phase III study. Shares of LQDA have surged 99% year to date, and the Zacks Consensus Estimate for 2026 earnings per share has moved to $2.57 from $2.97 in the past 60 days.
Liquidia Technologies IncYutrepia sales and patient uptake drive growth, with strong prescription numbers.
United Therapeutics CorporationYutrepia's success poses competitive threat to Tyvaso and Tyvaso DPI.
Johnson & Johnson